Insight Molecular Diagnostics Inc. (IMDX)
Q2 2026Earnings receipt·reported Aug 10, 2026 · After Close·quarter ended Jun 30, 2026
EPS Beat 0.0%
The street expected
EPS consensus
-$0.23
By basis
-$0.24 GAAP
adjusted / GAAP consensus, per stockanalysis
Revenue consensus
$437.5K
The company printed
EPS (adjusted)
($0.23)
GAAP ($0.31)
Revenue
$239.0K
EPS vs street
0.0%
against -$0.23 — stockanalysis adjusted consensus, pre-report snapshot
verified against the 8-K on EDGAR ↗ · figures published 4:55 PM ET
Why this page exists
Every public surface destroys the “expected” number at the moment it matters: the actual overwrites it, and post-hoc surprise figures get computed against restated consensus. This receipt was frozen from Wall St Engine’s nightly expectation archive before the print and joined to figures verified from the release itself. It does not update, and it cannot be reconstructed after the fact.
receipt frozen 2026-08-10 20:55 UTC · actuals last refined 2026-08-13 03:56 UTC · IMDX company page